Heidelberg
The research areas Hepatitis, Infections of the Immunocompromised Host and Tuberculosis are co-managed from Heidelberg. Furthermore, Heidelberg scientists coordinate the DZIF-wide Biobanking unit—since 2021 part of the DZIF infrastructure Bioresources, Biodata and Digital Health—with a focus on tissue banking. In addition to participating in the DZIF Clinical Trial Unit with a “First-In-Human (FIH)” unit for early clinical trials, Heidelberg researchers are working on combating malaria, developing antiviral therapy concepts for viral emerging infectious diseases, controlling HIV, as well healthcare-associated and antibiotic-resistant bacteria, and developing imaging methods to visualise infections in systems of varying complexity.